Physician profile
Ruba Memon
NPI 1033632393
$3,136.90
in general payments reported to CMS, 2019-2025
21 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $640 · 2023: $346 · 2024: $786 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $913.39 | 2023-2025 | |
| Janssen Biotech, INC. | $590.58 | 2022-2025 | Tremfya |
| Amgen INC. | $432.31 | 2023-2025 | Tavneos, Otezla, Otezla |
| Ucb, INC. | $196.48 | 2022-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $186.30 | 2024-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $119.44 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $113.31 | 2024-2025 | Saphnelo |
| Pfizer INC. | $95.51 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $81.88 | 2024-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $79.41 | 2023-2024 | Lupkynis |
| Smith+Nephew, INC. | $47.04 | 2022 | |
| Radius Health, INC. | $46.69 | 2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $41.79 | 2025 | Orencia |
| Sandoz INC. | $33.52 | 2025 | Hyrimoz |
| Lilly USA, LLC | $30.56 | 2024 | Taltz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $28.58 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.83 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $22.38 | 2024 | Arcalyst |
| Grifols USA, LLC | $18.51 | 2022 | |
| Horizon Therapeutics Plc | $16.59 | 2023 | Krystexxa |
| Kiniksa Pharmaceuticals, LTD. | $15.80 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruba Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.